-
in discovering potential therapeutic candidates to target mitochondria vulnerability, including a nucleoside analog, small GTPase inhibitor, natural plant extract, monoclonal and bispecific antibodies
-
-Oncology are looking for several highly motivated and creative Postdoctoral Fellows. The group conducts the most forefront science and is highly productive with publications in high-impact journals such as
-
-Oncology are looking for several highly motivated and creative Postdoctoral Fellows. The group conducts the most forefront science and is highly productive with publications in high-impact journals such as
-
-Oncology are looking for several highly motivated and creative Postdoctoral Fellows. The group conducts the most forefront science and is highly productive with publications in high-impact journals such as
-
. The Li group conducts the most forefront science and is highly productive with publications in high-impact journals in the past five years, Nature Cancer (2023), Blood (2022, 2019, 2019), Blood Cancer
-
conduct research in discovering potential therapeutic candidates to target mitochondria vulnerability, including a nucleoside analog, small GTPase inhibitor, natural plant extract, and monoclonal and
-
in discovering potential therapeutic candidates to target mitochondria vulnerability, including a nucleoside analog, small GTPase inhibitor, natural plant extract, and monoclonal and bispecific
-
and Immuno-Oncology are looking for several highly motivated and creative Postdoctoral Fellows. The group conducts the most forefront science and is highly productive with publications in high-impact
-
in discovering potential therapeutic candidates to target mitochondria vulnerability, including a nucleoside analog, small GTPase inhibitor, natural plant extract, and monoclonal and bispecific
-
targeted therapies. 5) The role of extracellular vesicles/exosomes as in cancer pathogenesis and their role as disease biomarkers. Our group performs cutting-edge research in GI oncology, is very productive